Answers are grounded in this paper and cite their sources.
Economic analysis outlines healthcare needs and resource allocation for Duchenne muscular dystrophy in India, suggesting improvements in treatment services.
Despite some limitations, the study provides directions for planning healthcare services for DMD in India by developing standard treatment guidelines, allocation of resources through national health schemes for carrier screening and prenatal diagnosis, promoting evidence-based therapeutic practices, and regulation to curb unscientific therapies. Baseline data are available to decide cost-effectiveness of public expenditure for disease-modifying drugs for DMD.
No takes yet. Share an insight, caveat, or question.
Antony et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: